Item 8.01 Other Events.
On March 17, 2021, Sage Therapeutics, Inc. issued a press release announcing
topline data for the 30 mg dose cohort and additional interim data for the 50 mg
dose cohort in the ongoing Phase 3 open-label SHORELINE study evaluating
zuranolone (SAGE-217) in the treatment of patients with major depressive
disorder. A copy of the press release is filed as Exhibit 99.1 hereto and is
incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press release issued by Sage Therapeutics, Inc. on March 17, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses